Collaborations

Alliance Medical Radiopharmacy

Radboud Translational Medicine and Alliance Medical started a collaboration in 2018 for the development, production and sales of radiopharmaceuticals.

Alliance Medical consists of the Diagnostic Imaging en Radiopharmaceuticals divisions.

Alliance Medical Diagnostic Imaging, a European operating organization with over 3,000 employees, combines service excellence en innovative medical imaging technology to support optimal patient treatment. It does its by using MRI, CT and PET/CT systems in both mobile units and fully equipped state-of-the-art diagnostic centers.

Alliance Medical Radiopharmaceuticals has an extensive network of cyclotron facilities in several European countries for the production, distribution and sales of radiopharmaceuticals. Thanks to this network, it can always offer the best possible solution to its customers. Through this collaboration, we aim to optimally meet the needs of hospitals'Nuclear Medicine departments and thus contribute to further optimization of medical imaging.

ImaginAb

The collaboration between RTM (Radboud Translational Medicine) and ImaginAb began in March 2020:

'As one of our Contract Development and Manufacturing Organizations (CDMOs), RTM has been instrumental in producing 89Zr Crefmirlimab Berdoxam doses for distribution to clinical sites across Europe. By January 2022, RTM was fully qualified to manufacture doses for ImaginAb, and it is anticipated that they will produce over 100 doses in 2024.

This partnership is advantageous as it enhances ImaginAb’s dose manufacturing capabilities in Europe, ensuring a more robust supply chain for our clinical studies, including those conducted by ImaginAb, Pharma, and Investigator-Initiated Trials (IITs).'

Life Molecular Imaging

In 2023, Radboud Translational Medicine entered into a collaboration with Life Molecular Imaging (LMI), an internationally operating company dedicated to the development of innovative PET tracers for the early diagnosis of chronic and life-threatening diseases. The partnership was established through the existing relationship with Alliance Medical, which is also responsible for product distribution.

As part of this collaboration, RTM is responsible for the production and quality control of Neuraceq® (18F Florbetaben), a radioactive tracer used for brain PET imaging. Neuraceq® is designed to bind to β-amyloid neuritic plaques—one of the hallmark features of Alzheimer’s disease (AD).

This tracer allows physicians to determine at an early stage whether cognitive decline may be caused by Alzheimer’s disease or another condition. By enabling direct visualization of amyloid plaques, Neuraceq® supports more accurate diagnoses and earlier, better-informed clinical decisions for patients and their families.

For RTM, this partnership represents a meaningful expansion of its portfolio in the field of neurodegenerative disease diagnostics. For hospitals and patients in the Netherlands, Belgium, and Germany, the collaboration with LMI and Alliance Medical ensures access to high-quality and reliable molecular imaging—crucial for identifying disease at an early stage.

The first commercial batch of Neuraceq® was successfully produced on May 21, 2024.

ABX

The collaboration between ABX (ABX advanced biochemical compounds) and RTM (Radboud Translational Medicine) started in 2019. As one of ABX’s trusted Contract Manufacturing Organizations (CMOs), RTM has played a key role in the production and supply of Radelumin (¹⁸F-PSMA-1007) for several clinical trials and routine clinical use across PET centres in the Netherlands and Germany. Currently, Radelumin is produced approximately five times per week at RTM.

ABX is a global frontrunner in radiopharmaceuticals, with a focus on PET-tracers. The company develops and produces compounds and components for all types of radiotracers – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in a GMP environment. ABX developed ¹⁸F-PSMA-1007, which is now approved in selected countries in Europe.

Radelumin (¹⁸F-PSMA-1007) is a radioactive diagnostic agent used for positron emission tomography (PET). It helps in imaging prostate-specific membrane antigen (PSMA)-positive lesions in adult patients. This is particularly useful for detecting suspected recurrence of prostate cancer after primary curative therapy, based on rising serum prostate-specific antigen (PSA) levels. Additionally, it is also used for the primary staging of patients with high-risk prostate cancer prior to curative treatment.